NCT02005848已完成2 期
Phase II Study to Evaluate the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Kamada, Ltd.
- 入组人数
- 70
- 试验地点
- 4
- 主要终点
- Beta cell function
研究概览
简要总结
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Study Evaluating the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes.
The study objectives are:
- To assess the efficacy of intravenous AAT in treatment of new onset Type 1 Diabetes
- To assess the safety and tolerability of intravenous AAT in new onset Type 1 Diabetes pediatric and young adult population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 8 Years 至 25 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject (or parent/guardian) willing and able to sign an informed consent
- •Age 8-25 (inclusive) years
- •Recently diagnosed with T1DM
- •Basal C-peptide ≥ 0.2 pmol/mL
- •Positive for at least one diabetes-related autoantibody
- •Ability and consent to comply with completion of patient diary
- •No significant abnormalities in serum hematology, serum chemistry
- •No significant abnormalities in urinalysis
- •No significant abnormalities in ECG
- •For women of child bearing potential, non-pregnant, non-lactating female patients
排除标准
- •IgA deficient subjects
- •Subjects who have received an active/ live virus vaccine within 4 weeks of the screening date
- •Subjects who have received treatment with corticosteroid medication within 2 months prior to screening or any immunosuppressant or cytostatic agent within 6 months prior to screening
- •Individuals with a history of severe immediate hypersensitivity reactions, including anaphylaxis, to plasma products
- •Clinically significant intercurrent illnesses
- •Pregnant or lactating women
- •Current use of any medication known to influence glucose tolerance
- •Current or prior (within the last 60 days prior to screening visit) use of metformin, sulfonylureas, glinides, thiazolidinediones, exenatide, liraglutide, DPP-IV inhibitors or amylin.
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Other)
Alpha-1 Antitrypsin (Glassia)
Experimental
120 mg/kg body weight
干预措施: Alpha-1 Antitrypsin (Biological)
Alpha1 Antitrypsin (Glassia)
Experimental
60 mg/kg body weight
干预措施: Alpha-1 Antitrypsin (Biological)
结局指标
主要结局
Beta cell function
时间窗: 12 months from baseline
Beta cell function (measured by C peptide)
次要结局
- Insulin dose(12 months from baseline)
- Hypoglycemic episodes(12 months from baseline)
- Beta cell function(12 months from baseline)
- Safety parameters(12 months from baseline)
- Glycemic control(12 months from baseline)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
A Study of Hemay005 in Adult With Atopic DermatitisHemay005, Atopic DermatitisNCT05769946Ganzhou Hemay Pharmaceutical Co., Ltd79
终止
2 期
A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseBehçet DiseaseNCT04609397Tianjin Hemay Pharmaceutical Co., Ltd89
已完成
2 期
A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee OsteoarthritisMedial Compartment Knee OsteoarthritisKnee OsteoarthritisNCT02087904AbbVie350
招募中
2 期
A Study for the Treatment of Dry Eye in Postmenopausal WomenPostmenopausal Women With DEDNCT06133166Changchun GeneScience Pharmaceutical Co., Ltd.240
Unknown
2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine ProphylaxisMigraine ProphylaxisNCT02021474AgoneX Biopharmaceuticals, Inc.130